Merck pays $588M for bispecific to defend Keytruda’s kingdom from emerging threat

cafead

Administrator
Staff member
  • cafead   Nov 14, 2024 at 10:22: AM
via Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF bispecific antibody.

article source